RE:RE:RE:RE:RE:RE:RE:RE:I wonder if the market 99942Apophis wrote: Rumpl3StiltSkin wrote
When the data from this Covid effort come in later this year, and more data from the Cancer fronts, who knows what the spec value will/should/ be....?
Ok Rumpl3StiltSkin on speculation should we get hard numbers and what most people on this board think my wild guess falls into a wide range between 15 and 19 dollars that is with a high multiple awarded for the future PE (price to earnings ratio) for initial year of profit.
So funny because thats for only 2 of how many other indications that this company (TLT) will add to its list.
I actually think that the Covid angle could get us to those valuations first, mostly on spec. 1433 could be the 6th or 7th Vaccine to get approved. It will be first amongst it's peers though in that it will also be an effective therapy and will not need any updates for future strains. It's only downside is it probably doesn't confer t-cell immunity, but I'm not sure about that.